PharmaShots Weekly Snapshot (June 10 – 14, 2019)

AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-IIIb DIALIZE Study to Treat Hyperkalaemia in Patients with End-Stage Renal Disease

1.AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-IIIb DIALIZE Study to Treat Hyperkalaemia in Patients with End-Stage Renal Disease

Published: Jun 14, 2019 | Tags: AstraZeneca, Reports, Results, Lokelma, sodium zirconium cyclosilicate, P-IIIb, DIALIZE Study, Treat, Hyperkalaemia, End-Stage Renal Disease

Upsher-Smith Signs an Agreement with Dr. Reddy’s Laboratories to Acquire its Two Neurology Products

2. Upsher-Smith Signs an Agreement with Dr. Reddy’s Laboratories to Acquire its Two Neurology Products

Published: Jun 14, 2019 | Tags: Upsher-Smith, Signs, Agreement, Dr. Reddy’s Laboratories, Acquires, Neurological Products

Eli Lilly to Report Positive Results of Taltz (ixekizumab) in P-IIIb/IV SPIRIT-H2H Study for Active Psoriatic Arthritis #EULAR2019

3. Eli Lilly to Report Positive Results of Taltz (ixekizumab) in P-IIIb/IV SPIRIT-H2H Study for Active Psoriatic Arthritis #EULAR2019

Published: Jun 14, 2019 | Tags: Eli Lilly, Reports, Positive, Results, Taltz, ixekizumab, P-IIIb/IV, SPIRIT-H2H Study, Active Psoriatic Arthritis, #EULAR2019

BeiGene Reports Updated Results of Tislelizumab in P-II Study in Chinese Patients with R/R Classical Hodgkin Lymphoma #EHA2019

4. BeiGene Reports Updated Results of Tislelizumab in P-II Study in Chinese Patients with R/R Classical Hodgkin Lymphoma #EHA2019

Published: Jun 14, 2019 | Tags: BeiGene, Reports, Updated, Results, Tislelizumab, P-II, Study, Chinese Patients, R/R, Classical Hodgkin Lymphoma, #EHA2019

Bristol Myer Reports Results of Orencia (abatacept) in P-IV Early AMPLE Study for Moderate-to-Severe Rheumatoid Arthritis #EULAR2019

5. BMS Reports Results of Orencia (abatacept) in P-IV Early AMPLE Study for Moderate-to-Severe Rheumatoid Arthritis #EULAR2019

Published: Jun 13, 2019 | Tags: BMS, Reports, Data, Orencia, abatacept, P-IV, Early AMPLE, Study, Moderate, Severe, Rheumatoid Arthritis, #EULAR20196

Amgen and Allergan's Kanjinti (trastuzumab, biosimilar) Receive FDA’s Approval for All Approved Indications of Herceptin

6.Amgen and Allergan’s Kanjinti (trastuzumab, biosimilar) Receive the US FDA’s Approval for All Approved Indications of Herceptin

Published: Jun 13, 2019 | Tags: Amgen, Allergan, Kanjinti, trastuzumab, biosimilar, Receive, FDA, Approval, Approved, Indications, Herceptin

Sobi Acquires Novimmune’s Emapalumab with its All Related Assets to Strengthen its Focus in Hematology and Immunology

7.Sobi Acquires Novimmune’s Emapalumab with its All Related Assets to Strengthen its Focus in Hematology and Immunology

Published: Jun 12, 2019 | Tags:Sobi, Acquires, Novimmune, Emapalumab, Related Assets, Hematology, Immunology

Celltrion Reports Results of CT-P13 SC (infliximab, biosimilar) in a Clinical Study for Rheumatoid Arthritis #EULAR2019

8.Celltrion Reports Results of CT-P13 SC (infliximab, biosimilar) in a Clinical Study for Rheumatoid Arthritis #EULAR2019

Published: Jun 11, 2019 | Tags: Celltrion, Reports, Results, CT-P13 SC, infliximab, biosimilar, Clinical Study, Rheumatoid Arthritis, #EULAR2019

Pfizer Reports Results of Xeljanz XR (tofacitinib) in the P-IIIB/IV ORAL Shift Study for Moderate to Severe Rheumatoid Arthritis #EULAR2019

9. Pfizer Reports Results of Xeljanz XR (tofacitinib) in the P-IIIB/IV ORAL Shift Study for Moderate to Severe Rheumatoid Arthritis #EULAR2019

Published: Jun 12, 2019 | Tags: Pfizer, Reports, Results, Xeljanz XR, tofacitinib, P-IIIB/IV, ORAL Shift, Study, Moderate, Severe Rheumatoid Arthritis, #EULAR2019

Genentech Reports Positive Results of Rituxan (rituximab) in P-III PEMPHIX Study to Treat Patients with Moderate to Severe Pemphigus Vulgaris

10. Genentech Reports Positive Results of Rituxan (rituximab) in P-III PEMPHIX Study to Treat Patients with Moderate to Severe Pemphigus Vulgaris

Published: Jun 12, 2019 | Tags: Genentech, Reports, Positive, Results, Rituxan, rituximab, P-III, PEMPHIX Study, Treat, Patients, Moderate, Severe, Pemphigus Vulgaris

AbbVie Reports Results of Upadacitinib in Two P-III Studies for Rheumatoid Arthritis #EULAR

11.AbbVie Reports Results of Upadacitinib in Two P-III Studies for Rheumatoid Arthritis #EULAR2019

Published: June 12, 2019 | Tags: AbbVie, Reports, Results, Upadacitinib, Two, P-III, Studies, Rheumatoid Arthritis, #EULAR

Novo Nordisk Reports Cardiovascular Outcomes of Oral Semaglutide in PIONEER 6 Study for Type 2 Diabetes

12. Novo Nordisk Reports Cardiovascular Outcomes of Oral Semaglutide in PIONEER 6 Study for Type 2 Diabetes

Published: June 11, 2019 | Tags: Novo Nordisk, Reports, Cardiovascular Outcomes, Oral Semaglutide, PIONEER 6, Study, Type 2 Diabetes

Genentech Reports Acceptance of sBLA for Rituxan (rituximab) to Treat Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in Children with 2 Years and Older

13. Genentech Reports Acceptance of sBLA for Rituxan (rituximab) to Treat Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in Children with 2 Years and Older

Published: June 11, 2019 | Tags: Genentech, Reports, Acceptance, sBLA, Rituxan, rituximab, Granulomatosis Polyangiitis, Microscopic Polyangiitis, Children, 2 Years, Older

Biogen Reports New Data of its Biosimilar Anti-TNF Portfolio at European Congress of Rheumatology (EULAR) 2019

14. Biogen To Report New Data of its Biosimilar Anti-TNF Portfolio at European Congress of Rheumatology (EULAR) 2019

Published: June 11, 2019 | Tags: Biogen, Reports, New Data, Biosimilar, Anti-TNF, Portfolio, European Congress of Rheumatology, 2019

Janssen Reports Cardiovascular Outcomes of Invokana (canagliflozin) in P-III CREDENCE Study for Type 2 Diabetes and Chronic Kidney Disease

15.Janssen Reports Cardiovascular Outcomes of Invokana (canagliflozin) in P-III CREDENCE Study for Type 2 Diabetes and Chronic Kidney Disease

Published: June 11, 2019 | Tags: Janssen, Reports, Cardiovascular Outcomes, Invokana, canagliflozin, P-III, CREDENCE, Study, Type 2, Diabetes, Chronic Kidney Disease

Janssen Signs an Exclusive Worldwide License and Option Agreement with Genmab for its HexaBody-CD38

16.Janssen Signs an Exclusive Worldwide License and Option Agreement with Genmab for its HexaBody-CD38

Published: June 11, 2019 | Tags: Janssen, Signs, Exclusive, Worldwide, License, Option, Agreement, Genmab, HexaBody-CD38

Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval for 1L Treatment of Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

17. Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval for 1L Treatment of Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

Published: June 11, 2019 | Tags: Merck, Keytruda, pembrolizumab, Receives, FDA, Approval, 1L, Treatment, Metastatic, Unresectable, Recurrent, Head and Neck Squamous Cell Carcinoma

Eli Lilly and Boehringer Ingelheim Report Cardiovascular Outcomes of Tradjenta (linagliptin) in CAROLINA Study for Type 2 Diabetes

18. Eli Lilly and Boehringer Ingelheim Report Cardiovascular Outcomes of Tradjenta (linagliptin) in CAROLINA Study for Type 2 Diabetes

Published: June 10, 2019 | Tags: Eli Lilly, Boehringer Ingelheim, Report, Cardiovascular Outcomes, Tradjenta, linagliptin, CAROLINA, Study, Type 2, Diabetes

Abbvie Reports Two Years Data of Skyrizi (risankizumab) in P-III IMMhance Study for Moderate to Severe Plaque Psoriasis #WCD2019

19. Abbvie Reports Two Years Data of Skyrizi (risankizumab) in P-III IMMhance Study for Moderate to Severe Plaque Psoriasis #WCD2019

Published: June 11, 2019 | Tags: Abbvie, Reports, Two Years, Data, Skyrizi, risankizumab, P-III, IMMhance, Study, Moderate, Severe, Plaque Psoriasis, #WCD2019

Abbvie Reports Two Years Data of Skyrizi (risankizumab) in P-III IMMhance Study for Moderate to Severe Plaque Psoriasis #WCD2019

20. Innovative Health Solution’s IB-Stim Receives FDA’s Clearance for the Treatment of Functional Abdominal Pain in Irritable Bowel Syndrome

Published: June 11, 2019 | Tags: Innovative Health Solution, IB-Stim, Receives, FDA, Clearance, Treatment, Functional Abdominal Pain, Irritable Bowel Syndrome

Eli Lilly Reports Results of Taltz (ixekizumab) in 5 Years P-III Study for Plaque Psoriasis #WCD2019

21. Eli Lilly Reports Results of Taltz (ixekizumab) in 5 Years P-III Study for Plaque Psoriasis #WCD2019

Published: June 11, 2019 | Tags: Eli Lilly, Reports, Results, Taltz, ixekizumab, 5 Years, P-III, Study, Plaque Psoriasis, #WCD2019

Roche’s Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA’s Accelerated Approval for Relapsed/Refractory Lymphoma

22.Roche’s Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA’s Accelerated Approval for Relapsed/Refractory Lymphoma

Published: June 11, 2019 | Tags: Roche, Polivy, polatuzumab vedotin-piiq, Combination, Therapy, Receives, FDA, Accelerated, Approval, Relapsed, Refractory, Lymphoma

Medtronic and Tidepool Collaborates to Develop Interoperable Automated Insulin Pump System for Diabetes Management

23. Medtronic and Tidepool Collaborates to Develop Interoperable Automated Insulin Pump System for Diabetes Management

Published: June 07, 2019 | Tags: Medtronic, Tidepool, Collaborates, Develop, Interoperable Automated Insulin Pump System, Diabetes Management

Merck To Acquire Tilos Therapeutics for ~ $773M

24. Merck To Acquire Tilos Therapeutics for ~ $773M

Published: June 10, 2019 | Tags: Merck, Acquire, Tilos Therapeutics, $773M

25. Theramex Signs an Exclusive License Agreement with Therapeutics MD to Commercialize Bijuva and Imvexxy Outside the US

Theramex Signs an Exclusive License Agreement with Therapeutics MD to Commercialize Bijuva and Imvexxy Outside the US

Published: June 07, 2019 | Tags: Theramex, Signs, Exclusive, License, Agreement, Therapeutics MD, Commercialize, Bijuva, Imvexxy, Outside, US

26.Eli Lilly Reports Results of Ultra Rapid Lispro (URLi) in Two P-III Studies for Type 1 And Type 2 Diabetes

Eli Lilly Reports Results of Ultra Rapid Lispro (URLi) in Two P-III Studies for Type 1 And Type 2 Diabetes

Published: June 06, 2019 | Tags: Eli Lilly, Reports, Results, Ultra Rapid Lispro, URLi, Two, Studies, Type 1, Type 2, Diabetes